Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients Story by: Published Date Story by: Topics covered: Share This: Article Content A new University of California San Diego study offers compelling evidence that GLP-1 receptor agonists the class of drugs behind Ozempic, Wegovy and Mounjaro, for example may do more than regulate blood sugar and weight
Research Applications Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist investigated in laboratory and experimental research settings for its interaction with metabolic, appetite-related, and glucose-regulation pathways
Trichoscopy A non-invasive diagnostic technique using a specialised microscope (dermoscope) to examine the scalp and hair follicles at high magnification
Although the FDA regulates dietary supplements, this is minimal compared with the agencys oversight of prescription medications
A large study published in Nature in April 2026 identified specific variants in the GLP1R and GIPR genes that predict differential weight loss and side effect risk on GLP-1 medications
in vitro and animal studies have linked thymosin beta-4 overexpression to increased tumor size and metastasis in several cancer types (including colorectal and pancreatic cancer), leading researchers to flag a theoretical cancer-promotion risk, particularly for anyone with an active malignancy or recent cancer history Self-reported effects compiled from user and case reports, not controlled trials, include injection-site redness or itching, transient fatigue, and headache
US$ 28.57
US$ 29.54
US$ 20.89
